预计本报告期利润总额同比增长107.53%-111.30%、归属于上市公司股东的净利润同比增长 120.43%-129.37%。影响利润变动的主要原因：（1）面对境内药品销售价格下行，营收承压的挑战，公 司锚定国际化发展方向，深耕海外业务布局，在推动原有出口品种销售额保持稳步增长的同时，积极推 进研发项目境外申报，本报告期研发品种注射用紫杉醇（白蛋白结合型）美国注册申请获批，公司凭借 高效的境外经营举措，获批后快速形成良好销售，驱动整体营收实现明显增长；（2）上年同期公司计 提中融信托理财产品公允价值变动损失，而本报告期无此类因素影响；（3）本报告期资产减值损失有 所减少；以上主要原因促使整体经营业绩扭亏为盈。 格隆汇1月26日丨*ST双成(002693.SZ)公布，预计2025年归属于上市公司股东的净利润1,600万元～2,300 万元，同比扭亏为盈，扣除非经常性损益后的净利润1,400万元～2,000万元，同比扭亏为盈，营业收入 25,000万元～29,000万元。 ...

Core Viewpoint - *ST Shuangcheng (002693.SZ) has been recognized as a high-tech enterprise in Ningbo for the first batch of 2025, which will provide tax benefits for the next three years [1] Group 1: Company Recognition - Ningbo Shuangcheng Pharmaceutical Co., Ltd., a subsidiary of Hainan Shuangcheng Pharmaceutical Co., Ltd., has been certified as a high-tech enterprise by the Ningbo Municipal High-tech Enterprise Recognition Management Work Leading Group [1] - The high-tech enterprise certificate number is GR202533101446, issued on December 8, 2025, and is valid for three years [1] Group 2: Tax Benefits - Following the recognition, Ningbo Shuangcheng will enjoy a preferential corporate income tax rate of 15% for three consecutive years, as per the relevant provisions of the Corporate Income Tax Law of the People's Republic of China [1] Group 3: Impact on Financial Performance - The recognition will not have an impact on the company's current operating performance [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： H ...

Group 1 - The core point of the article is that *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable bortezomib ANDA product [1] Group 2 - The company announced the FDA approval on its investor interaction platform [1]

Group 1 - The core viewpoint of the article is that *ST Shuangcheng (002693.SZ) has confirmed that several of its products are included in the medical insurance catalog [1] - The products that are included in the medical insurance catalog are: Thymosin injection, Somatostatin injection, Famotidine injection, Clindamycin hydrochloride injection, Chuanxiong phosphate injection, and Octreotide acetate injection [1] - The company has not submitted an application for its product, Paclitaxel injection (albumin-bound), in the domestic market [1]

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

Core Viewpoint - The company *ST Shuangcheng has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for injectable bortezomib, indicating that the product is bioequivalent and therapeutically equivalent to the reference drug [1] Group 1: FDA Approval - The U.S. FDA has completed a comprehensive technical review of the ANDA submitted by the company [1] - The approval confirms that the company's product is equivalent in terms of biological and therapeutic effects to the original drug [1] Group 2: Approved Indications - The approved indications for the injectable bortezomib include: 1. Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] 2. Part of a combination therapy for previously untreated multiple myeloma patients under 65 years old, used for high-dose chemotherapy with autologous stem cell rescue following prior induction therapy [1] 3. Treatment for multiple myeloma patients who have received at least one prior therapy and whose disease has progressed [1] 4. Treatment of adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： ...

Group 1 - The company reported interim results for the six months ending September 30, 2025, with revenue of approximately HKD 324 million, representing a year-on-year increase of 7.97% [1] - The loss attributable to the company's owners was HKD 83.395 million, which narrowed by 24.07% compared to the previous year [1] - The basic loss per share was HKD 0.01 [1]

Core Viewpoint - China Resources Transportation (00269) reported a revenue of approximately HKD 324 million for the six months ending September 30, 2025, representing a year-on-year increase of 7.97% [1] Financial Performance - The company recorded a loss attributable to shareholders of HKD 83.395 million, which is a reduction of 24.07% compared to the previous year [1] - The basic loss per share was HKD 0.01 [1]